Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,377 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine.
Maagdenberg H, Vijverberg SJ, Bierings MB, Carleton BC, Arets HG, de Boer A, Maitland-van der Zee AH. Maagdenberg H, et al. Among authors: de boer a. Paediatr Drugs. 2016 Aug;18(4):251-60. doi: 10.1007/s40272-016-0176-2. Paediatr Drugs. 2016. PMID: 27142473 Free PMC article. Review.
Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors.
Maitland-van der Zee AH, Klungel OH, Stricker BH, Monique Verschuren WM, Kastelein JJ, Leufkens HG, de Boer A. Maitland-van der Zee AH, et al. Among authors: de boer a. Atherosclerosis. 2002 Aug;163(2):213-22. doi: 10.1016/s0021-9150(01)00725-0. Atherosclerosis. 2002. PMID: 12052467 Review.
Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men.
Maitland-van der Zee AH, Klungel OH, Stricker BH, Veenstra DL, Kastelein JJ, Hofman A, Witteman JC, Leufkens HG, van Duijn CM, de Boer A. Maitland-van der Zee AH, et al. Among authors: de boer a. Pharmacogenetics. 2004 Jan;14(1):53-60. doi: 10.1097/00008571-200401000-00006. Pharmacogenetics. 2004. PMID: 15128051
Methodological and statistical issues in pharmacogenomics.
Peters BJ, Rodin AS, de Boer A, Maitland-van der Zee AH. Peters BJ, et al. Among authors: de boer a. J Pharm Pharmacol. 2010 Feb;62(2):161-6. doi: 10.1211/jpp.62.02.0002. J Pharm Pharmacol. 2010. PMID: 20487194 Review.
[Genetic variations affect drug safety and efficacy].
Harmsze AM, Deneer VH, Maitland-van der Zee AH, de Boer A, Klungel OH. Harmsze AM, et al. Among authors: de boer a. Ned Tijdschr Geneeskd. 2010;154:A1503. Ned Tijdschr Geneeskd. 2010. PMID: 20699026 Review. Dutch.
Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.
Verhoef TI, Redekop WK, van Schie RM, Bayat S, Daly AK, Geitona M, Haschke-Becher E, Hughes DA, Kamali F, Levin LÅ, Manolopoulos VG, Pirmohamed M, Siebert U, Stingl JC, Wadelius M, de Boer A, Maitland-van der Zee AH; EU-PACT group. Verhoef TI, et al. Among authors: de boer a. Pharmacogenomics. 2012 Sep;13(12):1405-17. doi: 10.2217/pgs.12.124. Pharmacogenomics. 2012. PMID: 22966889 Review.
1,377 results